GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Insider Ownership

BIOA (Bioage Labs) Insider Ownership : 3.64 % (As of Apr. 13, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bioage Labs's insider ownership is 3.64%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bioage Labs's Institutional Ownership is 54.78%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bioage Labs's Float Percentage Of Total Shares Outstanding is 0.00%.


Bioage Labs Insider Ownership Historical Data

The historical data trend for Bioage Labs's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Insider Ownership Chart

Bioage Labs Historical Data

The historical data trend for Bioage Labs can be seen below:

2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Insider Ownership 3.86 3.63 3.63 3.63 3.63 3.63 3.64

Bioage Labs Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Bioage Labs Business Description

Traded in Other Exchanges
N/A
Address
1445A South 50th Street, Richmond, CA, USA, 94804
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.